NASDAQ
NPCE
Last Price
US $14.51
Valuation
Financial
Performance
Cash flow to debt coverage
NeuroPace, Inc. cash flow to debt ratio of -15.54% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
NeuroPace, Inc.'s free cash flow has increased -37.89% from $-18.25M last year to $-11.34M, signaling increasing performance
Debt-to-equity ratio
NeuroPace, Inc.'s debt to equity ratio is 4.87, which means that the company's assets are unhealthy financed, signaling financial risk.
Debt-to-equity trend
NeuroPace, Inc.'s debt has decreased relative to shareholder equity from 9.15 last year to 4.87 today, signaling strengthened financials
Net debt to EBITDA
NeuroPace, Inc. has negative EBITDA, making leverage ratio unreliable
Interest coverage
NeuroPace, Inc.'s interest coverage ratio is -2.46, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
NeuroPace, Inc.'s profit margin has increased (-36.21%) in the last year from -33.97% to -21.67%, signaling increasing performance
Current ratio
NeuroPace, Inc.'s short-term assets of $94.07M exceed its short-term liabilities of $17.81M
Return on assets
NeuroPace, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
NeuroPace, Inc.'s return on equity of -120.74%, is lower than 15.00%, indicating bad performance
Earnings quality
NeuroPace, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
NeuroPace, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
NeuroPace, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
NeuroPace, Inc. has negative free cash flow, indicating cash burn
Earnings growth
NeuroPace, Inc.'s yearly earnings has increased -20.91% since last year from $-27.14M to $-21.46M, signaling increasing performance
Revenue growth
NeuroPace, Inc.'s yearly revenue has increased 25.13% since last year from $79.91M to $99.99M, signaling increasing performance
Return on invested capital
ROIC -19.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
NeuroPace, Inc.'s 3-year revenue CAGR of 29.99% is positive, indicating growing revenue over the past 3 years
Revenue consistency
NeuroPace, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance
Return on equity consistency
NeuroPace, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
NeuroPace, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
NeuroPace, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
NeuroPace, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
NeuroPace, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
NeuroPace, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
NeuroPace, Inc. has a price-to-book ratio of 34.71x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
NeuroPace, Inc. has a price-to-sales ratio of 5.04x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-119.68%
Return on equity
ROIC: -18.43%
Valuation History
-
Price to Earnings
EV/EBITDA: -44.9X
Cash flow
Profit margin
0.69%
Cash flow
13.83%
Fair Value
Market $14.51
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.